Evidence map›Paper›PMID 36978885›Full record

ArticleAntioxidants (Basel, Switzerland)2023

The Role of Pyrazolo[3,4-d]pyrimidine-Based Kinase Inhibitors in The Attenuation of CCl

Diana K Ghobrial, Nefertiti El-Nikhely, Eman Sheta, Hanan M Ragab, Sherif A F Rostom, Hesham Saeed, Ahmed Wahid

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Diana K GhobrialDepartment of Biotechnology, Institute of Graduate Studies and Research, Alexandria University, Alexandria 21526, Egypt.ORCID 0009-0003-8752-2433
Nefertiti El-NikhelyDepartment of Biotechnology, Institute of Graduate Studies and Research, Alexandria University, Alexandria 21526, Egypt.
Eman ShetaDepartment of Pathology, Faculty of Medicine, Alexandria University, Alexandria 21321, Egypt.ORCID 0000-0001-9018-5229
Hanan M RagabDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21500, Egypt.ORCID 0000-0001-5716-9307
Sherif A F RostomDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21500, Egypt.
Hesham SaeedDepartment of Biotechnology, Institute of Graduate Studies and Research, Alexandria University, Alexandria 21526, Egypt.ORCID 0000-0001-6600-1338
Ahmed WahidDepartment of Pharmaceutical Biochemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21500, Egypt.
Alexandria University · EG

Funding

The Science, Technology & Innovation Funding Authority (STDF) 44634
6 · The paper itself

Abstract

Liver Fibrosis can be life-threatening if left untreated as it may lead to serious, incurable complications. The common therapeutic approach is to reverse the fibrosis while the intervention is still applicable. Celecoxib was shown to exhibit some antifibrotic properties in the induced fibrotic liver in rats. The present study aimed to investigate the possible antifibrotic properties in CCl

Indexed as

celecoxibkinase inhibitorliver fibrosispyrazolo[3,4-d]pyrimidineTGF-β

Identifiers

PMID36978885
PMCPMC10045301
OpenAlexW4323313565

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read4
measurements read18
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.